The "Alzheimer's Gene" Has a Secret Life in Parkinson's

One of the most frustrating aspects of Parkinson's is its unpredictability. For some, it is a slow-burning condition that remains manageable for decades, while for others, it moves with aggressive speed, affecting walking and thinking much earlier in the journey. A new study published in Neurology has shed light on a major reason for this disparity: a specific genetic variant that acts as a "silent partner" in the condition. Most people have heard of the APOE ε4 gene, though usually in the context of Alzheimer’s. It is often dubbed the "Alzheimer’s gene" because carrying it increases the risk of developing dementia later in life. However, researchers at Tor Vergata University Hospital in Rome have discovered that this gene is also busy at work in people with Parkinson's—and it makes its presence felt from the very first day of diagnosis. The researchers looked at a group of newly diagnosed ("de novo") individuals who had not yet started any medication. They compared those who carried the APOE ε4 gene against those who did not. The differences were stark. The carriers didn't just have Parkinson's; they had a distinct, more intense subtype of the condition. Right from the starting line, these individuals showed significantly worse motor symptoms. They struggled more with bradykinesia (slowness of movement) and had greater difficulties with gait and stability than their non-carrier counterparts. It wasn't just physical, either; biological tests of their spinal fluid revealed that they already had lower levels of specific proteins, a hallmark usually associated with the buildup of plaques in Alzheimer's. This suggests that for these individuals, the biology of Parkinson's and Alzheimer's might be overlapping from the very beginning. Perhaps the most fascinating finding came from looking at the electrical wiring of their brains using high-density EEG. The brain operates on different electrical frequencies, like a radio. The study found that carriers of the gene had a "power failure" in the alpha band—the frequency that helps organise information and movement. Low alpha connectivity was directly linked to their trouble with walking and early signs of cognitive strain. Conversely, they had an overdrive of activity in the beta band. In Parkinson's, too much beta activity is often the culprit behind stiffness and slowness. It creates a state of "rigid" communication between brain areas, making smooth movement nearly impossible. While this might sound discouraging for those who carry the gene, it is actually a vital step forward for science. For years, we have treated Parkinson's as one single thing. This study proves that it is not. By identifying this "aggressive subtype" early, doctors can stop guessing and start predicting. It suggests that in the future, a simple blood test could tell you if you are at risk for this faster progression. More importantly, it opens the door for "personalised medicine." If we know someone has this specific genetic driver, we might be able to offer them different therapies—perhaps even drugs originally designed for Alzheimer's—to protect their brain in ways that standard dopamine drugs simply cannot. It moves us away from a "one size fits all" approach and towards a future where treatment is as unique as your DNA.